Nuwellis secures the new American patent, strengthening her leader position in fluid management innovation

Minneapolis, July 15, 2025 (Globe Newswire) – Nuwellis, Inc. (NASDAQ: NUWE), a medical technology company focused on fluid management solutions, announced today the program by the American patent patent and American palette methods. “The patent was officially granted on July 15, 2025, further strengthening the increasing intellectual property portfolio of the company.

The patent covers the methods of improving the accuracy of fluid balance calculations by incorporating the density of replacement fluids and effluents – an error source known in continuous renal replacement therapy systems (CRRT) which use weight -based measurements. While most of the systems imply a default fluid density of 1 g / ml, the real fluid densities vary. This gap, if it is not corrected, can lead to clinically relevant fluid balance errors. The patented approach allows CRRT systems to take into account the density – user input via, machine measurement or derived data – resulting in monitoring of the more precise volumetric flow.

The patent joins the robust and croissant portfolio of Nuwellis, American patents pending linked to its system and its proprietary methods.

“The expansion of our intellectual property portfolio is a key element in our strategy,” said John Erb, managing director of Nuwels. “Each new patent is strengthening our commitment to strengthen long -term value thanks to the innovation that supports patients, clinicians and our future growth.”

This addition reflects the investment of Nuwels in the protection of progress in the management of extracorporeal fluids and strengthens its position in the field evolution of fluid management therapies.

For more information, visit www.nuwellis.com.

About Newwellis Nuwellis, Inc. (Nasdaq: Nuwe) is a company of medical devices dedicated to the transformation of the lives of patients suffering from fluid overload by science, collaboration and innovation. The company focuses on the marketing of the Aquadex smartflow^® Ultrafiltration therapy system. Nuwellis has its head office in Minneapolis, with a subsidiary in exclusive property in Ireland. For more information, visit www.nuwellis.com or visit us on LinkedIn or X, formerly known as Twitter.

About the Aquadex Smartflow^® System The Aquadex SmartFlow system offers clinically proven therapy using a simple, flexible and intelligent method to remove excess liquid from patients with hypervolemia (overload of fluids). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or prolonged (more than 8 hours in patients who need hospitalization) in adult and pediatric patients weighing 20 kg or more whose overload of liquid does not respond to medical management, including diuretics. All treatments must be administered by a health care provider, in an outpatient or hospital clinical framework, under the doctor’s prescription, both having received training in extracorporeal therapies.